Literature DB >> 18624732

Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus.

Marjoleine L Op den Brouw1, Rekha S Binda, Mark H van Roosmalen, Ulrike Protzer, Harry L A Janssen, Renate G van der Molen, Andrea M Woltman.   

Abstract

Chronic hepatitis B virus (HBV) infection is the result of an inadequate immune response towards the virus. Myeloid dendritic cells (mDC) of patients with chronic HBV are impaired in their maturation and function, resulting in more tolerogenic rather than immunogenic responses, which may contribute to viral persistence. The mechanism responsible for altered mDC function remains unclear. The HBV-infected patients display large amounts of HBV particles and viral proteins in their circulation, especially the surface antigen HBsAg, which allows multiple interactions between the virus, its viral proteins and DC. To assess whether HBV directly influences mDC function, the effects of HBV and HBsAg on human mDC maturation and function were investigated in vitro. As already described for internalization of HBV by DC, the present study shows that peripheral blood-derived mDC of healthy controls also actively take up HBsAg in a time-dependent manner. Cytokine-induced maturation in the presence of HBV or HBsAg resulted in a significantly more tolerogenic mDC phenotype as demonstrated by a diminished up-regulation of costimulatory molecules and a decreased T-cell stimulatory capacity, as assessed by T-cell proliferation and interferon-gamma production. In addition, the presence of HBV significantly reduced interleukin-12 production by mDC. These results show that both HBV particles and purified HBsAg have an immune modulatory capacity and may directly contribute to the dysfunction of mDC in patients with chronic HBV. The direct immune regulatory effect of HBV and circulating HBsAg particles on the function of DC can be considered as part of the mechanism by which HBV escapes immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18624732      PMCID: PMC2632689          DOI: 10.1111/j.1365-2567.2008.02896.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

Review 1.  Antigen decoding by T lymphocytes: from synapses to fate determination.

Authors:  A Lanzavecchia; F Sallusto
Journal:  Nat Immunol       Date:  2001-06       Impact factor: 25.606

Review 2.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

3.  Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection.

Authors:  M K Maini; C Boni; G S Ogg; A S King; S Reignat; C K Lee; J R Larrubia; G J Webster; A J McMichael; C Ferrari; R Williams; D Vergani; A Bertoletti
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

4.  Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.

Authors:  G J Webster; S Reignat; M K Maini; S A Whalley; G S Ogg; A King; D Brown; P L Amlot; R Williams; D Vergani; G M Dusheiko; A Bertoletti
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

5.  Point mutation in the S gene of hepatitis B virus for a d/y or w/r subtypic change in two blood donors carrying a surface antigen of compound subtype adyr or adwr.

Authors:  H Okamoto; M Imai; F Tsuda; T Tanaka; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

6.  Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.

Authors:  Y Shimizu; L G Guidotti; P Fowler; F V Chisari
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

7.  Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus.

Authors:  G Marinos; F Torre; S Chokshi; M Hussain; B E Clarke; D J Rowlands; A L Eddleston; N V Naoumov; R Williams
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

8.  Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.

Authors:  Renate G van der Molen; Dave Sprengers; Rekha S Binda; Esther C de Jong; Hubert G M Niesters; Johannes G Kusters; Jaap Kwekkeboom; Harry L A Janssen
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

9.  HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection.

Authors:  D Loirat; M Mancini-Bourgine; J-P Abastado; M-L Michel
Journal:  Int Immunol       Date:  2003-10       Impact factor: 4.823

10.  Recombinant HBsAg, an apoptotic-like lipoprotein, interferes with the LPS-induced activation of ERK-1/2 and JNK-1/2 in monocytes.

Authors:  Peter Vanlandschoot; Annelies Roobrouck; Freya Van Houtte; Geert Leroux-Roels
Journal:  Biochem Biophys Res Commun       Date:  2002-09-27       Impact factor: 3.575

View more
  75 in total

Review 1.  Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.

Authors:  Adam J Gehring; June Ann D'Angelo
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

Review 2.  Role of Tim-3 in hepatitis B virus infection: An overview.

Authors:  Yuan Liu; Li-Fen Gao; Xiao-Hong Liang; Chun-Hong Ma
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 3.  Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.

Authors:  Jieliang Chen; Zhenghong Yuan
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

Review 4.  Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?

Authors:  Sarene Koh; Antonio Bertoletti
Journal:  Med Microbiol Immunol       Date:  2014-12-16       Impact factor: 3.402

Review 5.  How to achieve immune control in chronic hepatitis B?

Authors:  Margo J H van Campenhout; Harry L A Janssen
Journal:  Hepatol Int       Date:  2014-09-06       Impact factor: 6.047

6.  Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.

Authors:  Yingjie Bian; Zheng Zhang; Zhichen Sun; Juanjuan Zhao; Danming Zhu; Yang Wang; Sherry Fu; Jingya Guo; Longchao Liu; Lishan Su; Fu-Sheng Wang; Yang-Xin Fu; Hua Peng
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

Review 7.  The role of innate immunity in HBV infection.

Authors:  Qiuju Han; Cai Zhang; Jian Zhang; Zhigang Tian
Journal:  Semin Immunopathol       Date:  2012-07-20       Impact factor: 9.623

8.  Clinical Significance of Quantitative HBsAg Titres and its Correlation With HBV DNA Levels in the Natural History of Hepatitis B Virus Infection.

Authors:  Vijay K Karra; Soumya J Chowdhury; Rajesh Ruttala; Sunil K Polipalli; Premashis Kar
Journal:  J Clin Exp Hepatol       Date:  2016-08-03

Review 9.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

Review 10.  Crosstalk between innate and adaptive immunity in hepatitis B virus infection.

Authors:  Li Wang; Kai Wang; Zhi-Qiang Zou
Journal:  World J Hepatol       Date:  2015-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.